We use cookies to understand how you use our site and to improve your experience.
This includes personalizing content and advertising.
By pressing "Accept All" or closing out of this banner, you consent to the use of all cookies and similar technologies and the sharing of information they collect with third parties.
You can reject marketing cookies by pressing "Deny Optional," but we still use essential, performance, and functional cookies.
In addition, whether you "Accept All," Deny Optional," click the X or otherwise continue to use the site, you accept our Privacy Policy and Terms of Service, revised from time to time.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
Novo Nordisk (NVO) Dips More Than Broader Market: What You Should Know
Read MoreHide Full Article
In the latest close session, Novo Nordisk (NVO - Free Report) was down 2.14% at $40.29. This move lagged the S&P 500's daily loss of 0.04%. Meanwhile, the Dow experienced a drop of 0.57%, and the technology-dominated Nasdaq saw an increase of 0.04%.
Shares of the drugmaker witnessed a gain of 12.03% over the previous month, beating the performance of the Medical sector with its loss of 0.72%, and underperforming the S&P 500's gain of 12.24%.
Analysts and investors alike will be keeping a close eye on the performance of Novo Nordisk in its upcoming earnings disclosure. The company's earnings report is set to go public on May 6, 2026. The company's upcoming EPS is projected at $0.87, signifying a 5.43% drop compared to the same quarter of the previous year. Meanwhile, the Zacks Consensus Estimate for revenue is projecting net sales of $11.13 billion, up 1.08% from the year-ago period.
For the entire fiscal year, the Zacks Consensus Estimates are projecting earnings of $3.34 per share and a revenue of $45.44 billion, representing changes of -15.66% and -2.87%, respectively, from the prior year.
Investors might also notice recent changes to analyst estimates for Novo Nordisk. Recent revisions tend to reflect the latest near-term business trends. Hence, positive alterations in estimates signify analyst optimism regarding the business and profitability.
Based on our research, we believe these estimate revisions are directly related to near-term stock moves. To capitalize on this, we've crafted the Zacks Rank, a unique model that incorporates these estimate changes and offers a practical rating system.
The Zacks Rank system, running from #1 (Strong Buy) to #5 (Strong Sell), holds an admirable track record of superior performance, independently audited, with #1 stocks contributing an average annual return of +25% since 1988. Over the last 30 days, the Zacks Consensus EPS estimate has witnessed a 0.6% decrease. Novo Nordisk is holding a Zacks Rank of #3 (Hold) right now.
Looking at its valuation, Novo Nordisk is holding a Forward P/E ratio of 12.34. For comparison, its industry has an average Forward P/E of 13.88, which means Novo Nordisk is trading at a discount to the group.
Also, we should mention that NVO has a PEG ratio of 9.8. This popular metric is similar to the widely-known P/E ratio, with the difference being that the PEG ratio also takes into account the company's expected earnings growth rate. As the market closed yesterday, the Large Cap Pharmaceuticals industry was having an average PEG ratio of 2.23.
The Large Cap Pharmaceuticals industry is part of the Medical sector. Currently, this industry holds a Zacks Industry Rank of 169, positioning it in the bottom 31% of all 250+ industries.
The Zacks Industry Rank gauges the strength of our individual industry groups by measuring the average Zacks Rank of the individual stocks within the groups. Our research shows that the top 50% rated industries outperform the bottom half by a factor of 2 to 1.
Be sure to use Zacks.com to monitor all these stock-influencing metrics, and more, throughout the forthcoming trading sessions.
Zacks' 7 Best Strong Buy Stocks (New Research Report)
Valued at $99, click below to receive our just-released report
predicting the 7 stocks that will soar highest in the coming month.
View the Zacks #1 Rank List
Image: Bigstock
Novo Nordisk (NVO) Dips More Than Broader Market: What You Should Know
In the latest close session, Novo Nordisk (NVO - Free Report) was down 2.14% at $40.29. This move lagged the S&P 500's daily loss of 0.04%. Meanwhile, the Dow experienced a drop of 0.57%, and the technology-dominated Nasdaq saw an increase of 0.04%.
Shares of the drugmaker witnessed a gain of 12.03% over the previous month, beating the performance of the Medical sector with its loss of 0.72%, and underperforming the S&P 500's gain of 12.24%.
Analysts and investors alike will be keeping a close eye on the performance of Novo Nordisk in its upcoming earnings disclosure. The company's earnings report is set to go public on May 6, 2026. The company's upcoming EPS is projected at $0.87, signifying a 5.43% drop compared to the same quarter of the previous year. Meanwhile, the Zacks Consensus Estimate for revenue is projecting net sales of $11.13 billion, up 1.08% from the year-ago period.
For the entire fiscal year, the Zacks Consensus Estimates are projecting earnings of $3.34 per share and a revenue of $45.44 billion, representing changes of -15.66% and -2.87%, respectively, from the prior year.
Investors might also notice recent changes to analyst estimates for Novo Nordisk. Recent revisions tend to reflect the latest near-term business trends. Hence, positive alterations in estimates signify analyst optimism regarding the business and profitability.
Based on our research, we believe these estimate revisions are directly related to near-term stock moves. To capitalize on this, we've crafted the Zacks Rank, a unique model that incorporates these estimate changes and offers a practical rating system.
The Zacks Rank system, running from #1 (Strong Buy) to #5 (Strong Sell), holds an admirable track record of superior performance, independently audited, with #1 stocks contributing an average annual return of +25% since 1988. Over the last 30 days, the Zacks Consensus EPS estimate has witnessed a 0.6% decrease. Novo Nordisk is holding a Zacks Rank of #3 (Hold) right now.
Looking at its valuation, Novo Nordisk is holding a Forward P/E ratio of 12.34. For comparison, its industry has an average Forward P/E of 13.88, which means Novo Nordisk is trading at a discount to the group.
Also, we should mention that NVO has a PEG ratio of 9.8. This popular metric is similar to the widely-known P/E ratio, with the difference being that the PEG ratio also takes into account the company's expected earnings growth rate. As the market closed yesterday, the Large Cap Pharmaceuticals industry was having an average PEG ratio of 2.23.
The Large Cap Pharmaceuticals industry is part of the Medical sector. Currently, this industry holds a Zacks Industry Rank of 169, positioning it in the bottom 31% of all 250+ industries.
The Zacks Industry Rank gauges the strength of our individual industry groups by measuring the average Zacks Rank of the individual stocks within the groups. Our research shows that the top 50% rated industries outperform the bottom half by a factor of 2 to 1.
Be sure to use Zacks.com to monitor all these stock-influencing metrics, and more, throughout the forthcoming trading sessions.